Venrock Healthcare Capital Partners

Activity in this selectionBiotech

By stage

Series A1

Series B1

Series C+1

Biotech3

United States2

United Kingdom1

3 in this selection

May 6

Develops inobrodib, a first-in-class oral p300/CBP inhibitor for relapsed or refractory multiple myeloma

$220MSeries D

Role not disclosed

Feb 18

Develops novel therapies to reduce the burden of neurodegenerative diseases

$175MSeries A

Role not disclosed

Jan 12

Develops next-generation therapies for immune-mediated inflammatory and fibrotic diseases

$250MSeries B

Role not disclosed